Piramal Pharma cuts reliance on Chinese raw materials to reduce risk

by@business

Summary

Piramal Pharma, an Indian contract drug manufacturer, has significantly reduced its dependence on Chinese raw materials to mitigate concentration risk. This decision aligns with a broader trend among Indian pharmaceutical manufacturers who are diversifying their supply chains in response to geopolitical concerns and the need for resilience in sourcing. The move also positions Indian firms to better support US pharmaceutical supply chains, as there is a growing interest from Western buyers to shift orders away from concentrated sources.

Analysis

Piramal Pharma: Piramal Pharma is an Indian contract development and manufacturing organization (CDMO) providing pharmaceutical services to global clients. The company is actively reducing its reliance on Chinese raw materials to lower supply chain concentration risks, with its chairperson recently emphasizing India's role as a reliable partner for the US pharmaceutical industry during discussions at the Bloomberg New Economy Forum. Industry Momentum: Small and mid-sized Indian pharma companies report increased interest from Western buyers seeking to shift orders away from concentrated sources. US-India Pharma Ties: Indian firms are positioning themselves to support US pharmaceutical supply chains through expanded manufacturing capabilities and reduced external dependencies. Supply Chain Diversification: Indian pharmaceutical manufacturers are pursuing alternatives to Chinese suppliers as Western buyers diversify sourcing amid geopolitical and resilience concerns.

Categories

macro

Related sources

View Original Tweet